Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Primary Objective:
To assess the overall safety of lixisenatide once daily treatment in monotherapy over 24 and 52 weeks in patients with type 2 diabetes in Japan
Secondary Objective:
To assess the effects of lixisenatide once daily treatment in monotherapy over 24 and 52 weeks on:
Full description
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
oAmylase and/or lipase >3 times the upper limit of the normal laboratory range (ULN);
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Primary purpose
Allocation
Interventional model
Masking
361 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal